News about Global Pharma

Wesper Revolutionizes Sleep Apnea Diagnosis with FDA-Cleared, Cannula-Free Technology

Without capturing this core signal, critical events like hypopneas can be missed, misclassified, or misunderstood. As clinical research and expert consensus increasingly affirm, airflow isn't optional—it's essential.

Global Pharma | 16/05/2025 | By Manvi |  265

Marksans Pharma's UK Subsidiary Relonchem Secures Marketing Authorisation for Gabapentin from UKMHRA

Relonchem Ltd. has received marketing authorisation for its product Gabapentin 50 mg/ml oral solution.

Global Pharma | 15/05/2025 | By Manvi |  259

Sanofi to Invest USD 20 Billion in US by 2030 to Expand R&D and Manufacturing

Sanofi has announced plans to invest at least $20 billion in the United States by 2030, significantly boosting R&D and manufacturing to support the launch of new therapies and strengthen the domestic supply chain.

Global Pharma | 15/05/2025 | By Manvi |  181

Genesys Spine Launches Stasys-C 3DP, a Zero-Profile 3D-Printed Cervical Standalone System

Genesys Spine has announced the commercial launch of the Stasys-C™ 3DP Cervical Standalone System, a 3D-printed, zero-profile cervical interbody solution designed to simplify anterior cervical procedures while promoting early fusion.

Global Pharma | 15/05/2025 | By Manvi |  178

Cariflex Inaugurates World's Largest Polyisoprene Latex Plant in Singapore

With an investment of USD 355 million, the plant is the largest of its kind in the world and will significantly expand Cariflex's production capacity to meet the growing demand for high-quality synthetic latex for medical and protective applications.

Global Pharma | 15/05/2025 | By Manvi |  446

Standard Glass Partners with Japan's AGI to Manufacture Glass-Lined Shell and Tube Heat Exchangers in India

Standard Glass Lining Technology (SGLTL) in collaboration with Japan’s AGI Group and its affiliate GL HAKKO will manufacture glass-lined shell and tube heat exchangers in India. The production is estimated to commence by Q4, FY26.

Global Pharma | 14/05/2025 | By Manvi |  671

Zydus Secures EIR from USFDA for Ambernath API Manufacturing Facility

Zydus Lifesciences has received an establishment inspection report (EIR) from the United States Food and Drug Administration (USFDA). The EIR has been classified under the no action indicated (NAI) category.

Global Pharma | 14/05/2025 | By Manvi |  390

USFDA Completes Inspection at Solara's Ambernath Facility with Zero Form 483 Observations

Solara Active Pharma Sciences Ltd. announced that its Ambernath API manufacturing facility has successfully completed a USFDA inspection with zero Form 483 observations, confirming the site’s compliance with regulatory standards.

Global Pharma | 14/05/2025 | By Manvi |  494

CuraTeQ Biologics Secures Approval for Biosimilar Zefylti from UK's MHRA

Aurobindo Pharma announced that its subsidiary CuraTeQ Biologics has received UK MHRA approval for Zefylti, a filgrastim biosimilar for treating neutropenia, marking its second MHRA-approved biosimilar.
<br />

Global Pharma | 14/05/2025 | By Manvi |  443

Caplin Steriles Receives USFDA Approval for Haloperidol Decanoate Injection

Caplin Steriles Ltd., a subsidiary of Caplin Point Ltd., gets an entry into the US market with the final approval from Abbreviated New Drug Application (ANDA) for Haloperidol Decanoate Injection.

Global Pharma | 14/05/2025 | By Manvi |  388